Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Area of Science:

• Cardiology
• Pulmonology
• Interventional Radiology

Background:

• Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe condition caused by organized blood clots in pulmonary arteries.
• Pulmonary endarterectomy (PEA) is a standard treatment for proximal CTEPH, but it is not suitable for all patients.
• Riociguat is the only FDA-approved medication for CTEPH, recommended for inoperable cases or post-PEA residual disease.

Purpose of the Study:

• To review the history, indications, procedures, and complications of Balloon Pulmonary Angioplasty (BPA).
• To evaluate BPA as a potential alternative treatment for CTEPH.
• To discuss the future outlook of BPA in managing CTEPH.

Main Methods:

• Literature review of existing studies on BPA for CTEPH.
• Analysis of procedural techniques and outcomes associated with BPA.
• Summary of complications and management strategies for BPA.

Main Results:

• BPA is emerging as a viable and promising treatment option for CTEPH.
• The procedure shows potential benefits, especially for patients with inoperable CTEPH.
• Understanding BPA's history and techniques is crucial for its application.

Conclusions:

• Balloon Pulmonary Angioplasty (BPA) represents a significant advancement in CTEPH treatment.
• Further research and experience are needed to fully establish BPA's role and optimize its use.
• BPA may offer a valuable alternative for patients unsuitable for PEA or medical therapy alone.